PDGFRB and neoplasm: This study reveals for the first time a new mechanism by which ezetimibe acts on TNBC, that is, ezetimibe inhibits the growth of TNBC by inhibiting the activation of the PDGFRβ/AKT pathway, thereby inducing G1 blockade in tumor cells.